Cobimetinib and Lorbrena

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Lorlatinib may significantly reduce the blood levels of cobimetinib, which may make the medication less effective in treating your cancer. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme. Simulations using physiologically-based pharmacokinetic (PBPK) models suggest that cobimetinib exposures would decrease by 83% when coadministered with a potent CYP450 3A4 inducer and by 73% when coadministered with a moderate CYP450 3A4 inducer. The therapeutic efficacy of cobimetinib may be reduced.

MANAGEMENT: Concomitant use of cobimetinib with potent CYP450 3A4 inducers should generally be avoided.

Cobimetinib

Generic Name: cobimetinib

Brand name: Cotellic

Synonyms: n.a.

What is Cobimetinib?

Lorbrena

Generic Name: lorlatinib

Brand name: Lorbrena

Synonyms: n.a.

What is Lorbrena?